Compare DOCN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOCN | CYTK |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 10.7B |
| IPO Year | 2021 | 2004 |
| Metric | DOCN | CYTK |
|---|---|---|
| Price | $93.28 | $61.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 23 |
| Target Price | ★ $176.20 | $109.40 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.15 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $901,427,000.00 | $13,368,000.00 |
| Revenue This Year | $30.79 | $72.63 |
| Revenue Next Year | $54.38 | $181.06 |
| P/E Ratio | $204.11 | ★ N/A |
| Revenue Growth | ★ 15.48 | N/A |
| 52 Week Low | $37.84 | $57.92 |
| 52 Week High | $187.50 | $88.31 |
| Indicator | DOCN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 37.55 |
| Support Level | $73.66 | $59.21 |
| Resistance Level | $94.24 | $66.63 |
| Average True Range (ATR) | 9.38 | 1.98 |
| MACD | -3.85 | 0.33 |
| Stochastic Oscillator | 8.78 | 31.89 |
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.